Impax names new generics division president

HAYWARD, Calif. — Impax Laboratories on Monday announced the appointment of Douglas S. Boothe to the position of president of its generics division. Boothe will report directly to the specialty pharmaceutical company’s CEO and oversee its entire generics business. 

 

“Doug is an accomplished executive with extensive generic pharmaceutical leadership and business development experience that will be instrumental in growing our generics business,” Impax president and CEO Fred Wilkinson said. “We are delighted that Doug is joining the company at an important time, as we expand our generics portfolio through the pending acquisition of products from Teva Pharmaceutical Industries and affiliates of Allergan, and prepare the strategies to maximize the return from our near term potential ANDA (abbreviated new drug application) approvals.”

 

Boothe had previously served as Perrigo’s EVP and general manager, where he was responsible for U.S. pharmaceuticals, including generics and specialty. From August 2008 to December 2012, he was CEO of Actavis after serving as EVP and COO for two years. Recently, he was a director of the Generic Pharmaceutical Associaton.